Procter & Gamble Health share price today

Procter & Gamble Health Ltd's share price was ₹5,738.00 at the close on 4 November 2026. It has been falling for 4 weeks. That is 1.1% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Procter & Gamble Health Ltd is in stage 4. The phase helps read everything below.

In the last 52 weeks it traded between ₹4,779 and ₹6,839, and at that close it sat 47% of the way up from that low.

Over the last 11 years the share price moved +773% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Two changes stood out: revenue up on a year earlier for 6 quarters in a row and highest quarterly profit in 15 quarters.

1. Revenue up on a year earlier for 6 quarters in a row

   In the June 2026 quarter revenue was ₹364 crore, +7.4% on a year earlier.

2. Highest quarterly profit in 15 quarters

   Profit of ₹96 crore in the June 2026 quarter is the highest of the last 15 quarters.

For April to June 2026 (the quarter ended 30 June 2026), Procter & Gamble Health reported revenue of ₹364 crore, up 7.4% from ₹339 crore a year earlier, and a profit of ₹96.0 crore, up 45.5% from ₹66.0 crore.

Procter & Gamble Health results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

The newest call in our records is from 18 June 2026, about January to March 2026; a call about these results is not in our records yet.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Procter & Gamble Health closed at ₹5,738.00 on 4 November 2026, down 1.7% from ₹5,839.00 a year earlier (7 November 2025) and up 5.4% over five years. Its highest weekly close since March 2016 was ₹7,379.45 on 12 February 2021.

Procter & Gamble Health share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

562 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Procter & Gamble Health closed at ₹5,738.00, up 1.2% on the week and up 7.1% on the month. 27 Aug 2026: ex-date for a dividend of ₹45 a share.

Earlier

• Our read, 19 Jul 2026: With margins at cycle highs, any pricing pressure or input cost inflation will severely compress earnings.
• Results for April to June 2026: Revenue up 7.4% and profit up 45.5% on a year earlier.
• 18 Jun 2026: Procter & Gamble Health held its results call for January to March 2026. Management guided: Growth momentum expected sustainable through near-term.
• 12 Feb 2026: ex-date for an interim + special dividend of ₹160 a share.

Our read of the business

With margins at cycle highs, any pricing pressure or input cost inflation will severely compress earnings.

Our read after the January to March 2026 results, written 19 July 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.

Procter & Gamble Health paid ₹155 a share in regular dividends in the 12 months to 5 November 2026 (2 payments), a yield of 2.70% at the ₹5,738.00 close on 4 November 2026. The last was a dividend of ₹45 a share, ex-date 27 August 2026.

Procter & Gamble Health dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Procter & Gamble Health Ltd paid out 104% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for January to March 2026, held on 18 June 2026, Procter & Gamble Health's management guided: Growth momentum expected sustainable through near-term.

“For the 12-month fiscal year ended March 31, 2026, we reported sales of close to Rs 1,400 crores, which is up 16% versus the comparable period last year. The profit after tax was Rs 327 crores, which is up by 30% versus the comparable period last year.”Milind Thatte, on the call for January to March 2026

What management guided

• FY26 growth composition disclosed: mid-single digit volume contribution, remainder from pricing and product mix.
• NPPA pricing framework parameters: 10% maximum annual increase non-scheduled drugs, WPI-indexed increases for scheduled drugs.
• Innovation pipeline continuing with consumer-centric focus but details kept confidential.
• Margin trajectory: balanced approach to top-line and bottom-line growth with 30% profit growth in FY26 demonstrating capability.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for January to March 2026, 18 June 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.

Sustained operating margin at peak levels for another four quarters combined with new product launches that structurally alter the margin profile, confirming the shift is permanent rather than cyclical.

Each change stops working if

• : Consumer downtrading or increased competition in OTC wellness.

The main risks

• : Severe earnings compression if margins mean-revert. ⚠ estimate

Our read after the January to March 2026 results, written 19 July 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.

When Procter & Gamble Health reports July to September 2026, these are the 3 checks that show whether the story is still on course. First: Livogen Iron Gummies market position retention - achieved #1 Amazon category share in FY26; monitor Q1/H1 FY27 online channel data for whether position lasts and continues contributing growth; management emphasized exceeding expectations.

Procter & Gamble Health is on 2 of our India lists: Dividend stocks and Pharma stocks.

Procter & Gamble Health Ltd earned ₹96.0 Cr of net profit in the Jun 2026 quarter, +45.5% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year Mar 2026 profit was ₹327 Cr. Over 10 years profit has grown 15.3% a year on average. That is 26.4% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹66.0 Cr.

For the full year, Mar 2026 profit was ₹327 Cr (+39.7% on the year before).

Why profit moved: revenue changed +7.4% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +23.9% and revenue +12.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

FY26-Q4. revenue ₹370 Cr and profit ₹95 Cr as reported.

FY27-Q1. revenue ₹364 Cr and profit ₹96 Cr as reported.

Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters.

Procter & Gamble Health Ltd reported ₹364 Cr of revenue in the Jun 2026 quarter, +7.4% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 3.6% a year on average. The last full year, Mar 2026, came in at ₹1,408 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Management cited superior brand-building activities and product innovations in the preventive healthcare segment driving 19% YoY sales growth in Q4 FY26.

The last four reported quarters add to ₹1,433 Cr.

Mar 2026 revenue was ₹1,408 Cr, +50.7% on the year before.

Recent pace: the last four quarters grew +12.7% on average, against 3.6% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +12.6%, against +11.6% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +19.3%, against +33.1% a year (rolling over).

FY26-Q4. revenue ₹370 Cr and profit ₹95 Cr as reported.

FY27-Q1. revenue ₹364 Cr and profit ₹96 Cr as reported.

Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters.

Procter & Gamble Health Ltd's operating margin was 27.0% in the Jun 2026 quarter, about the same as the same quarter a year ago. Across 13 years it has been between 7.0% and 34.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.7 percentage points on the year while gross margin changed +1.3 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

FY26-Q4. revenue ₹370 Cr and profit ₹95 Cr as reported.

FY27-Q1. revenue ₹364 Cr and profit ₹96 Cr as reported.

Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters.

Over the last 3 years, 96% of Procter & Gamble Health Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In Mar 2026 it brought in ₹338 Cr of operating cash against ₹327 Cr of profit. After ₹13.0 Cr of spending on assets, ₹325 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 96% of profit came in as cash: the cash cycle got 36 days longer between Jun 2021 and Mar 2026, so more of each rupee of profit waits in the business before it arrives.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Procter & Gamble Health Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −13 days in Mar 2026, up from −49 days in Jun 2021. It spent ₹49.0 Cr on assets over the last 3 years. Customers take 43 days to pay, and stock sits for 137 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At Mar 2026 sales of ₹1,408 Cr, each day of that cycle ties up about ₹3.9 Cr, so roughly −₹50.0 Cr is tied up in the business at any time.

Mar 26: customers took 43 days to pay and stock sat for 137 days, about 4.5 months of sales sitting as stock, for a full cycle of −13 days, longer than Jun 2021's −49.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 137 days. Customers pay about 43 days after that. Suppliers are paid at 192 days. Together that makes the −13-day cycle.

Spending on assets: ₹49.0 Cr over the last 3 years, against ₹79.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹14.0 Cr (Mar 2026): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Procter & Gamble Health Ltd's P/E is 28.5×, near the low end of its own history: it has been lower only 31% of the time. Its usual P/E (the middle reading) is 35.0×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹214.99.